Mesna

METABOLITES

Product Details

CAT No.# CS-T-31881
Category Metabolites
CAS 19767-45-4
Molecular Weight 164.17
Molecular Formula C2H5NaO3S2
Stock Status: In-Stock
Purity: >98%
Melting Point: >240
Solubility: Water
Appearance: White to Off-White Solid
Synonyms: sodium 2-mercaptoethanesulfonate
Application Notes: Mesna reacts with acrolein and other urotoxic metabolites of oxazaphosphorines (cyclophosphamide or ifosfamide) to form stable, non-urotoxic compounds. Mesna does not have any antitumour activity, nor does it appear to interfere with the antitumour activity of antineoplastic drugs. This medication is used to protect the bladder wall from the harmful effects of some cancer-fighting drugs.
References: Tekeres, M., et al.: Clin. Ther., 4, 56 (1981), Brock, N., et al.: Eur. J. Cancer Clin Oncol., 18, 1377 (1982), James, C.A., et al.: Br. J. Clin. Pharmacol., 23, 561 (1987), Schoenike, S.E., et al.: Clin. Pharm., 9, 179 (1990),
Storage: 2-8°C
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
3. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
4. Benidipine D7
5. Lauroside D
6. Triazolam 13C D3
7. Icatibant impurity 1
8. BISPHENOL AF (RING-13C12)
9. 0.1% TFA in Water ULC-MS
10. Metamizole EP Impurity C HCl
11. Silodosin Metabolite D4
12. Brivaracetam Carboxylic acid metabolite [UCB 42145]
13. Terbuthylazine D5
14. tibolone (848)
15. (Z)-Dimethylvinphos
16. Silodosin Metabolite
17. 2-Phenoxymethanesulfonanilide
18. Nimesulide EP Impurity A
19. Acetone HPLC
20. Nandrolone Decanoate EP impurity F


SMILES:
O=[S](CCS)([O-])=O.[Na+]



This page contains information about Mesna Cas 19767-45-4 and its Metabolites.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."